Search

Roger H. Unger, M.D., a longtime Professor of Internal Medicine, a preeminent authority on glucagon and the development of diabetes, and the founding Director of the Touchstone Center for Diabetes Research at UT Southwestern Medical Center, died Aug. 22. He was 96.

ChatGPT, the artificial intelligence (AI) chatbot designed to assist with language-based tasks, can effectively extract data for research purposes from physicians’ clinical notes, UT Southwestern Medical Center researchers report in a new study.

UT Southwestern Medical Center has joined more than a dozen leading medical centers and Microsoft to form the Trustworthy & Responsible AI Network (TRAIN), a national group designed to set standards and safely explore applications of artificial intelligence (AI) in health care.

Using artificial intelligence (AI), researchers from UT Southwestern have developed a way to accurately predict which skin cancers are highly metastatic.

Children who had preexisting health problems or who lived in the Southern United States had a higher risk for severe health outcomes from acute COVID-19 infections, according to researchers at UT Southwestern Medical Center.

Using machine learning tools to analyze hundreds of proteins, UT Southwestern researchers have identified a group of biomarkers in blood that could lead to an earlier diagnosis of children with autism spectrum disorder (ASD) and, in turn, more effective therapies sooner.

Children who undergo expansive genetic sequencing may not be getting the thorough DNA analysis their parents were expecting, say experts at UT Southwestern Medical Center.

The holiday season is a time for celebration, but too much celebrating can be bad for your health.

Myron Frederick Weiner, M.D., Professor Emeritus of Psychiatry at UT Southwestern Medical Center and a noted clinical researcher in geriatric psychiatry and Alzheimer’s disease, died July 17 in Dallas. He was 89.

– In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells, ARO-HIF2, effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).